跳至主要内容
临床试验/CTRI/2012/03/002516
CTRI/2012/03/002516已完成4 期

An open label randomized clinical study to evaluate the impact of Proseventy efficacy and safety in dialysis patients. - IMPROVES STUDY

Panacea Biotec Ltd0 个研究点目标入组 180 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1 Patient willing to sign informed consent form.
  • 2 Age of patient is 18 years or above.
  • 3 Patients in the middle to high socioeconomic group.
  • 4 Serum albumin < 3.8g/100ml
  • 5 Patients on maintenance dialysis for atleast for 3 months.
  • 6 Adequate dialyzed as per investigator
  • 7 Absence of uremic symptoms
  • 8 Patients classified as malnourished as per criteria listed in Annexure 1 (Diagnostic criteria for PEW as ISRNM)

排除标准

  • 1 Patients who do not have clinical PEW as per Annexure 1
  • 2 Patients with systemic infection like TB or Malaria.
  • 3 Patients who are currently using/ have discontinued use of any nutritional supplement
  • 4 Plan for kidney transplantation within study period
  • 5 Females who are pregnant or breast feeding
  • 6 Life expectancy less than 6 month
  • 7 Patient changed from haemodialysis to peritoneal dialysis

研究者

相似试验